Cure Parkinson’s is a patient-led charity with the aim of raising money to fund and facilitate research into finding a cure for Parkinson’s disease.

Each year the Cure Parkinson’s International Linked Clinical Trials (iLCT) committee ranks and prioritises candidate therapies based on whether they are ready to be taken into clinical trial for Parkinson’s. Some agents that are not prioritised to move into trial are found to demonstrate great potential but require further research before being tested in people with Parkinson’s.

The iLCT Pipeline Research Acceleration Programme aims to accelerate the additional research required for therapeutic candidates evaluated by the iLCT committee that were not considered ready to move forward into clinical trials in people with Parkinson’s. The type of research covered by the programme may include preclinical, epidemiological, dose-finding, or target engagement research.

Every year the programme calls for expressions of interest and subsequent applications for funding based on specified project outlines developed by Cure Parkinson’s from the iLCT committee feedback, to test one or more therapies that has been evaluated by iLCT but requires further research before moving into clinical trial.

The therapies to be tested for the 2025 call for applications are Empagliflozin, Theracurmin, Pyridoxal-5′-phosphate and Alogliptin. Applications testing more than one of the candidate agents may be viewed more favourably, but a minimum of one of these therapies must be included in each application.

Applications are welcome from qualified scientists or clinicians based in an academic or research institutes anywhere in the world.

The maximum available per project is £250,000, although it is desirable that applicants request less. Projects can last for up to 18 months, although preferably shorter.